Las variantes más contagiosas de Covid que salen del Reino Unido y Sudáfrica empeorarán la pandemia antes de que la vacunación masiva pueda mejorarla. Algunas de las nuevas vacunas generan esperanza no solo para este año y sino incluso en décadas futuras. Parece cada vez más plausible que las mismas armas que usaremos para derrotar a Covid-19 también puedan vencer incluso otras enfermedades , incluido el cáncer, que mata a casi 10 millones de personas al año.
Comentarios
#8 El primer "best seller" de zombies fue el Nuevo Testamento.
¿Por qué detenernos ahí? Algún día podrán erradicar otras plagas, como los ciclistas o los franceses.
En otro hilo comparti esta noticia de 2019 pre-COVID: .
----
Se han avanzado decadas en el desarrollo de vacunas via mRNA. Se ha pasado de prueba de concepto con una decena de individuos a vacunacion masiva de miles de millones de personas. Como curiosidad hasta 2019, BioNTech estaba mas centrada en usar esta tecnica en la lucha contra el cancer [1], segun los articulo pre-COVID en la revista Nature. No me extrañaria ver en los proximos años alguna terapias para el cancer usando mRNA. 🙏
>> Researchers at BioNTech in Mainz, Germany, the manufacturer of the cancer vaccine that Kremer is receiving, reported in 2017 that all of the first 13 people with advanced-stage melanoma to receive the personalized immunotherapy — which is tailor-made to match the genetic profile of each person’s cancer — showed elevated immunity against the mutated bits of their tumours. As a result, these patients’ risk of developing new metastatic lesions was significantly reduced
[1] www.nature.com/articles/d41586-019-03072-8
Esto iría en
podriame , no?
#8 eres un terrorista lanzando bombas así aquí. SON ZOMBIES
O podrían traer una pandemia zombie, como se ha visto en películas
#2 la que más se asemeja sería soy leyenda, y en modo friki serian infectados no zombies (no mueren y reviven sino que se infectan)
Estoy abierto al dialogo jejeje
Y pasado mañana al cambio climático.
No puedo leerla por el muro de pago, aun así no voto negativo porque la considero interesante. Para quién sí la pueda leer le pido que me ilustre: siempre que se ha argumentado "no hay vacuna para el cáncer y ya ha salido la de la covid" o incluso sin tener en cuenta esta pandemia, una de las respuestas es que el cáncer no es una única enfermedad, se trata de muchas. Sin embargo, en la entradilla lo mencionan como una única. ¿En el desarrollo de la noticia se aclara este matiz? Gracias.
#5
A mi no me ha salido el muro de pago. Aqui esta el texto:
---
The night is darkest just before dawn, they say. Dark it certainly is right now. The more contagious variants of SARS-CoV-2 coming out of the U.K. and South Africa will make the pandemic worse before mass vaccination can make it better.
But take another look at some of these new vaccines. And then contemplate the dawn to come — not just its first rays in the coming months but also the bright light of future years and decades. It looks increasingly plausible that the same weapons we’ll use to defeat Covid-19 can also vanquish even grimmer reapers — including cancer, which kills almost 10 million people a year.
The most promising Covid vaccines use nucleic acids called messenger RNA, or mRNA. One vaccine comes from the German firm BioNTech SE and its U.S. partner Pfizer Inc. The other is from the U.S. company Moderna Inc. (its original spelling was ModeRNA, its ticker is MRNA). Another is on the way from CureVac NV, also based in Germany.
Ordinary vaccines tend to be inactivated or weakened viruses which, when injected into the body, stimulate an immune response that can later protect against the live pathogen. But the process of making such vaccines requires various chemicals and cell cultures. This takes time and provides opportunities for contamination.
mRNA vaccines don’t have these problems. They instruct the body itself to make the offending proteins — in this case, the ones that wrap around the viral RNA of SARS-CoV-2. The immune system then homes in on these antigens, practicing for the day when the same proteins show up with the coronavirus attached.
Therein lies mRNA’s bigger promise: It can tell our cells to make whatever protein we want. That includes the antigens of many other diseases besides Covid-19.
In its day-to-day function, mRNA takes instructions from its molecular cousin, the DNA in our cell nuclei. Stretches of the genome are copied, which the mRNA carries into the cytoplasm, where little cellular factories called ribosomes use the information to churn out proteins.
BioNTech and Moderna shortcut this process, by skipping the whole fiddly business in the nucleus with the DNA. Instead, they first figure out what protein they want — for example, a spike on the coat around a virus. Then they look at the sequence of amino acids that makes this protein. From that they derive the precise instructions the mRNA must give.
This process can be relatively fast, which is why it took less than a year to make the vaccines, a pace previously unimaginable. It’s also genetically safe — mRNA can’t go back into the nucleus and accidentally insert genes into our DNA.
Researchers since the 1970s have had a hunch that you can use this technique to fight all sorts of maladies. But as usual in science, you need huge amounts of money, time and patience to sort out all the intermediary problems. After a decade of enthusiasm, mRNA became academically unfashionable in the 1990s. Progress seemed halting. The main obstacle was that injecting mRNA into animals often caused fatal inflammation.
Enter Katalin Kariko — a Hungarian scientist who immigrated to the U.S. in the 1980s and has heroically devoted her entire career to mRNA, through its ups and downs. In the 1990s, she lost her funding, was demoted, had her salary cut and suffered other setbacks. But she stuck with it. And then, after battling cancer herself, she made the crucial breakthrough.
In the 2000s, she and her research partner realized that swapping out uridine, one of mRNA’s “letters,” avoided causing inflammation without otherwise compromising the code. The mice stayed alive.
Her study was read by a scientist at Stanford University, Derrick Rossi, who later co-founded Moderna. It also came to the attention of Ugur Sahin and Ozlem Tureci, two oncologists who are husband and wife and co-founded BioNTech. They licensed Kariko’s technology and hired her. From the start, they were most interested in curing cancer.
Today’s weapons against cancer will one day seem as primitive an idea as flint axes in a surgery room. To kill a malignant tumor, you generally zap it with radiation or chemicals, damaging lots of other tissue in the process.
The better way to fight cancer, Sahin and Tureci realized, is to treat each tumor as genetically unique and to train the immune systems of individual patients against that specific enemy. A perfect job for mRNA. You find the antigen, get its fingerprint, reverse-engineer the cellular instructions to target the culprit and let the body do the rest.
Take a look at the pipelines of Moderna and BioNTech. They include drug trials for treating cancers of the breast, prostate, skin, pancreas, brain, lung and other tissues, as well as vaccines against everything from influenza to Zika and rabies. The prospects appear good.
Progress, admittedly, has been slow. Part of the explanation Sahin and Tureci give is that investors in this sector must put up oodles of capital and then wait for more than a decade, first for the trials, then for regulatory approvals. In the past, too few were in the mood.
Covid-19, fingers crossed, may turbo-charge all these processes. The pandemic has led to a grand debut of mRNA vaccines and their definitive proof of concept. Already, there are murmurs about a Nobel Prize for Kariko. Henceforth, mRNA will have no problems getting money, attention or enthusiasm — from investors, regulators and policymakers.
That doesn’t mean the last stretch will be easy. But in this dark hour, it’s permissible to bask in the light that’s dawning.
#5 >> Sin embargo, en la entradilla lo mencionan como una única. ¿En el desarrollo de la noticia se aclara este matiz? Gracias.
Antes del COVID, BioNTech y Moderna estaban centrados en la creacion de tratamientos para el cancer. Para ello estaban siguiendo dos caminos.
1) Tratamientos individualizados (tomando muestras geneticas de la persona y del tumor y creando una vacuna especifica para esa persona).
>> Along with other companies testing the same strategy, Moderna starts the process of making its personalized treatment by taking a pair of genetic profiles from each individual: one from a biopsy of the tumour, the other from a vial of healthy blood cells. Algorithms compare the DNA sequences of the two samples and produce a list of 34 targets, each encoding a different mutant protein expressed by the cancer that is predicted to be useful in training the immune system to attack the disease.
2) Vacunas generales que, aun siendo menos efectivas, pudiesen applicarse a a mas personas.
>> As personalized mRNA vaccines go through trials, Moderna, BioNTech and CureVac, based in Tübingen, Germany, are simultaneously developing off-the-shelf vaccine candidates as well. These ready-made vaccines are not as immunogenic as the most potent customized vaccines for people with highly mutated cancers, but they are potentially suitable for everyone. There is no lengthy customization process; no long waits, often of a month or more; and no added labour and manufacturing costs. They are ready for anyone who needs them.
En este articulo de 2019 (pre-covid) explica que estaban haciendo en aquellos tiempos.
https://www.nature.com/articles/d41586-019-03072-8
Si hubiera una vacuna del cáncer, ¿habría vacunación masiva a nivel mundial? Lo dudo.
#11 La vacuna contra el cancer, no funcionara como una vacuna contra un virus desafortunadamente. Como dicen arriba el cancer no es una unica enfermedad.